Previously, we reported similar attributes for analogous tetravalent bsAbs designed to inhibit immune checkpoints PD-L1 [19,20], CD47 [21,22], and CD73 (bsAb CD73xEGFR, manuscript under revision, JITC, Ploeg et al.)in a tumor-directed manner. This evidence concerns the gene CD47 and neoplasm.